Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis
- PMID: 33141955
- DOI: 10.1111/jgh.15329
Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis
Abstract
Background and aim: We aimed to estimate the worldwide incidence and prevalence, with focus on the geographical differences and temporal trends.
Methods: Studies on epidemiology of primary biliary cholangitis (PBC) in PubMed, Embase, and Cochrane Library were systematically retrieved from inception to October 2, 2020. Random-effect model was applied to estimate the pooled PBC incidence and prevalence rates. Subgroup analysis, meta-regression, and sensitivity analysis were conducted to find out the cause for heterogeneity.
Results: Out of 3974 records identified through database searching, 47 population-based studies were finally included. The pooled global incidence and prevalence of PBC were 1.76 and 14.60 per 100 000 persons, respectively. Both the PBC incidence and prevalence were lower in the Asia-Pacific region (0.84, 9.82 per 100 000 persons) than that in North America (2.75, 21.81 per 100 000 persons) and Europe (1.86, 14.59 per 100 000 persons) (P < 0.05). The incidence and prevalence showed an increasing tendency in all three regions, with the fastest growth of prevalence in North America (P < 0.05). We found a similar incidence and a lower prevalence of PBC in Northern Europe than that in Southern Europe. A higher incidence and prevalence were observed in female individuals and in the elderly (60-79).
Conclusion: The PBC incidence and prevalence varied widely across regions, with North America being the highest, followed by Europe, and the lowest in the Asia-Pacific region. Both the incidence and prevalence showed an increasing tendency worldwide, especially in North America.
Keywords: epidemiology; incidence; meta-analysis; prevalence; primary biliary cholangitis.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Comment in
-
Role of gut microbiota in primary biliary cholangitis.Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):597-599. doi: 10.1016/j.hbpd.2022.06.014. Epub 2022 Jun 26. Hepatobiliary Pancreat Dis Int. 2022. PMID: 35780017 No abstract available.
References
-
- Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatol. (Baltimore, Md) 2019; 69: 394-419.
-
- Lammers WJ, Hirschfield GM, Corpechot C et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149: 1804-1812 e1804.
-
- Efe C, Tascilar K, Henriksson I et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis. Am. J. Gastroenterol. 2019; 114: 1101-1108.
-
- Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J. Hepatol. 2012; 56: 1181-1188.
-
- Zeng N, Duan W, Chen S et al. Epidemiology and clinical course cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol. Int. 2019; 13: 788-799.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
